NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









MIMETAS

MIMETAS

Private
OegstgeestHealthcare & Life Scienceshttps://mimetas.com/

Last Round

Grant

Jul 7, 2024

Total Funding Raised

$32.96M

Company Overview

MIMETAS is a biotechnology company that develops and markets organ-on-a-chip products and 3D tissue models for drug development, compound testing, and research.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Application

Keywords

organ-on-a-chipmicrofluidicsdrug discoverytissue engineering3D cell culturetoxicology screeningpersonalized medicinedisease modelingphenotypic screeningcontract research organizationCROlab-on-a-chipin vitro modelshigh-throughput screeningpreclinical research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

MIMETAS Comparables

Compare MIMETAS with similar companies based on industry and business-model similarity.

MIMETAS comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Emulate
91%
CN Bio
90%
InSphero
89%

MIMETAS Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 7, 2024
GrantFeb 22, 2022
Series BApr 11, 2018
GrantDec 22, 2015
Series AOct 8, 2014
Grant
Sep 11, 2014

Key People

Founding team and executive leadership

Jos Joore

CEO And Co-founder

Founding Team

Paul Vulto

Chief Executive Officer, Board Member, Founder

Founding Team

Bas Trietsch

Chief Technology Officer

Executive Team

MIMETAS Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jan 27, 2025

    Attended SLAS 2025 and launched new OrganoPlate UniFlow technology.

  • Jan 27, 2025

    OrganoPlate UniFlow technology unveiled at SLAS 2025.

MIMETAS Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

MIMETAS Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about MIMETAS's valuation, stock price, and market status.

Firmographic Details

HeadquartersOegstgeest
Employee Range101
Year Founded2013
Last FundingJul 7, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.